Multiple sclerosis (MS) is the most common cause of non-traumatic disability in young adults, affecting an estimated 1million people worldwide. Although many novel agents have been approved for MS, the unmet medical need remains substantial. Existing drugs only reduce the rate of relapse, have a modest impact on slowing the progression of disease, and work poorly in non-inflammatory or so-called “progressive” forms of disease.
 
MS is broadly characterized into the following four disease classifications, namely (a) Relapsing-Remitting MS (RRMS), Secondary-Progressive MS (SPMS), (c) Primary-Progressive (PPMS), Progressive Relapsing (PRMS).